Antiplatelets in Stroke Prevention

ISSN: 1875-6212 (Online)
ISSN: 1570-1611 (Print)

Volume 15, 6 Issues, 2017

Download PDF Flyer

Current Vascular Pharmacology

This journal supports open access

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 36th of 63 in Peripheral Vascular Disease
  • 125th of 253 in Pharmacology & Pharmacy

Submit Abstracts Online Submit Manuscripts Online

Dimitri P. Mikhailidis
Academic Head, Department of Clinical Biochemistry
Royal Free Hospital Campus
University College London Medical School
University College London (UCL)
Pond Street
London, NW3 2QG

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 2.374
5 - Year: 2.25

Antiplatelets in Stroke Prevention

Current Vascular Pharmacology, 11(6): 803-811.

Author(s): Antonio Pinto, Domenico Di Raimondo, Antonino Tuttolomondo, Carmelo Butta and Giuseppe Licata.

Affiliation: Dipartimento Biomedico di Medicina Interna e Specialistica, Università degli Studi di Palermo, Palermo, Italy.


Stroke is the second cause of death worldwide and one of the leading cause of disability. Due to the high rate of recurrence, in high risk-patients (eg patients affected by atherosclerotic vascular disease), long-term antiplatelet therapy reduces the risk of vascular events such as non-fatal myocardial infarction, non-fatal stroke, or vascular death. The percentage of reduction of the events can be estimated in approximately 25%. These data justify the directions that are given to us by the current guidelines for prevention of secondary stroke, which recommend the broad use of antiplatelet therapy both for the secondary prevention of stroke in patients with a history of non-cardioembolic stroke or TIA.

As for the primary prevention indications are less accurate because the absolute benefi ts of aspirin in reducing the happening of vascular events, are generally much lower than in secondary prevention.

Although several trials have been investigated use of antiplatelet drugs in ischemic stroke patients, ascertaining the sure benefit, especially in secondary prevention in non-cardioembolic stroke, various issues remains unclarified, and new questions raises with the analysis of the results of available trials.


Antiplatelets, stroke, prevention.

Purchase Online Order Reprints Order Eprints Rights and Permissions

Article Details

Volume: 11
Issue Number: 6
First Page: 803
Last Page: 811
Page Count: 9
DOI: 10.2174/157016111106140128112915
Price: $58

Related Journals

Webmaster Contact: Copyright © 2016 Bentham Science